Goodrich Katherine 4
4 · Tarsus Pharmaceuticals, Inc. · Filed Jun 29, 2026
Research Summary
AI-generated summary of this filing
Tarsus (TARS) Director Katherine Goodrich Receives Equity Awards
What Happened Katherine Goodrich, a non-employee director of Tarsus Pharmaceuticals (TARS), was granted equity awards on 2026-06-25 consisting of 3,837 stock options and 2,417 restricted stock units (RSUs), for a total of 6,254 units. Both grants were reported at $0.00 per unit (award/grant). The options and RSUs are awards as part of director compensation rather than open‑market purchases or sales.
Key Details
- Transaction date: 2026-06-25; Form 4 filed: 2026-06-29 (filed within the normal reporting window).
- Grants: 3,837 options (derivative) and 2,417 RSUs — total 6,254 units. Reported price: $0.00 (award).
- Vesting: Options vest in full on the one‑year anniversary of the grant; RSUs convert to one share each and vest in full on the one‑year anniversary, both subject to continued service as a non‑employee director (Footnotes F1–F3).
- Transaction code: A (award/grant). No 10b5‑1 plan, tax‑withholding sale, or late filing indicated in the provided report.
- Shares owned after the transaction: not specified in the provided extract.
Context These grants appear to be standard annual equity compensation for service on the board, not purchases or sales that directly reveal buying/selling sentiment. The options are derivative awards that only convert to stock upon vesting and any subsequent exercise; the RSUs are contingent rights to receive shares upon vesting. Such awards are common for non‑employee directors and should be viewed as compensation rather than an immediate market investment.
Insider Transaction Report
- Award
Stock Option (right to buy)
[F1]2026-06-25+3,837→ 3,837 totalExercise: $64.34Exp: 2036-06-24→ Common Stock (3,837 underlying) - Award
Restricted Stock Units
[F2][F3]2026-06-25+2,417→ 2,417 total→ Common Stock (2,417 underlying)
Footnotes (3)
- [F1]Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.
- [F2]Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock.
- [F3]RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.